512 related articles for article (PubMed ID: 30578766)
41. METTL3 promotes tumour development by decreasing APC expression mediated by APC mRNA N
Wang W; Shao F; Yang X; Wang J; Zhu R; Yang Y; Zhao G; Guo D; Sun Y; Wang J; Xue Q; Gao S; Gao Y; He J; Lu Z
Nat Commun; 2021 Jun; 12(1):3803. PubMed ID: 34155197
[TBL] [Abstract][Full Text] [Related]
42. siRNA-mediated type 1 insulin-like growth factor receptor silencing induces chemosensitization of a human liver cancer cell line with mutant P53.
Niu J; Xu Z; Li XN; Han Z
Cell Biol Int; 2007 Feb; 31(2):156-64. PubMed ID: 17097318
[TBL] [Abstract][Full Text] [Related]
43. RNA m
Li J; Xie G; Tian Y; Li W; Wu Y; Chen F; Lin Y; Lin X; Wing-Ngor Au S; Cao J; He W; Wang H
Mol Ther; 2022 Apr; 30(4):1578-1596. PubMed ID: 35033632
[TBL] [Abstract][Full Text] [Related]
44. Mutant p53 gain of function: reduction of tumor malignancy of human cancer cell lines through abrogation of mutant p53 expression.
Bossi G; Lapi E; Strano S; Rinaldo C; Blandino G; Sacchi A
Oncogene; 2006 Jan; 25(2):304-9. PubMed ID: 16170357
[TBL] [Abstract][Full Text] [Related]
45. Mutant p53 drives cancer chemotherapy resistance due to loss of function on activating transcription of PUMA.
Huang Y; Liu N; Liu J; Liu Y; Zhang C; Long S; Luo G; Zhang L; Zhang Y
Cell Cycle; 2019 Dec; 18(24):3442-3455. PubMed ID: 31726940
[No Abstract] [Full Text] [Related]
46. TRIM29 Reverses Oxaliplatin Resistance of P53 Mutant Colon Cancer Cell.
Lei G; Liu S; Yang X; He C
Can J Gastroenterol Hepatol; 2021; 2021():8870907. PubMed ID: 33824865
[TBL] [Abstract][Full Text] [Related]
47. METTL3 facilitates tumor progression via an m
Li T; Hu PS; Zuo Z; Lin JF; Li X; Wu QN; Chen ZH; Zeng ZL; Wang F; Zheng J; Chen D; Li B; Kang TB; Xie D; Lin D; Ju HQ; Xu RH
Mol Cancer; 2019 Jun; 18(1):112. PubMed ID: 31230592
[TBL] [Abstract][Full Text] [Related]
48. RNA m
Luo G; Xu W; Zhao Y; Jin S; Wang S; Liu Q; Chen X; Wang J; Dong F; Hu DN; Reinach PS; Yan D
J Cell Physiol; 2020 Oct; 235(10):7107-7119. PubMed ID: 32017066
[TBL] [Abstract][Full Text] [Related]
49. p53 dominant-negative mutant R273H promotes invasion and migration of human endometrial cancer HHUA cells.
Dong P; Tada M; Hamada J; Nakamura A; Moriuchi T; Sakuragi N
Clin Exp Metastasis; 2007; 24(6):471-83. PubMed ID: 17636407
[TBL] [Abstract][Full Text] [Related]
50. METTL3-mediated N6-methyladenosine modification is critical for epithelial-mesenchymal transition and metastasis of gastric cancer.
Yue B; Song C; Yang L; Cui R; Cheng X; Zhang Z; Zhao G
Mol Cancer; 2019 Oct; 18(1):142. PubMed ID: 31607270
[TBL] [Abstract][Full Text] [Related]
51. SUMOylation of the m6A-RNA methyltransferase METTL3 modulates its function.
Du Y; Hou G; Zhang H; Dou J; He J; Guo Y; Li L; Chen R; Wang Y; Deng R; Huang J; Jiang B; Xu M; Cheng J; Chen GQ; Zhao X; Yu J
Nucleic Acids Res; 2018 Jun; 46(10):5195-5208. PubMed ID: 29506078
[TBL] [Abstract][Full Text] [Related]
52. miR-338-3p confers 5-fluorouracil resistance in p53 mutant colon cancer cells by targeting the mammalian target of rapamycin.
Han J; Li J; Tang K; Zhang H; Guo B; Hou N; Huang C
Exp Cell Res; 2017 Nov; 360(2):328-336. PubMed ID: 28928082
[TBL] [Abstract][Full Text] [Related]
53. Roles of METTL3 in cancer: mechanisms and therapeutic targeting.
Zeng C; Huang W; Li Y; Weng H
J Hematol Oncol; 2020 Aug; 13(1):117. PubMed ID: 32854717
[TBL] [Abstract][Full Text] [Related]
54. p53 gain-of-function cancer mutants induce genetic instability by inactivating ATM.
Song H; Hollstein M; Xu Y
Nat Cell Biol; 2007 May; 9(5):573-80. PubMed ID: 17417627
[TBL] [Abstract][Full Text] [Related]
55. Chemosensitivity of human colon cancer cells is influenced by a p53-dependent enhancement of ceramide synthase 5 and induction of autophagy.
Brachtendorf S; Wanger RA; Birod K; Thomas D; Trautmann S; Wegner MS; Fuhrmann DC; Brüne B; Geisslinger G; Grösch S
Biochim Biophys Acta Mol Cell Biol Lipids; 2018 Oct; 1863(10):1214-1227. PubMed ID: 30059758
[TBL] [Abstract][Full Text] [Related]
56. Surmounting cancer drug resistance: New insights from the perspective of N
Li B; Jiang J; Assaraf YG; Xiao H; Chen ZS; Huang C
Drug Resist Updat; 2020 Dec; 53():100720. PubMed ID: 32892147
[TBL] [Abstract][Full Text] [Related]
57.
Watanabe S; Tsuchiya K; Nishimura R; Shirasaki T; Katsukura N; Hibiya S; Okamoto R; Nakamura T; Watanabe M
Mol Cancer Res; 2019 Jul; 17(7):1459-1467. PubMed ID: 30988165
[TBL] [Abstract][Full Text] [Related]
58. Gain-of-Function Mutant p53 R273H Interacts with Replicating DNA and PARP1 in Breast Cancer.
Xiao G; Lundine D; Annor GK; Canar J; Ellison V; Polotskaia A; Donabedian PL; Reiner T; Khramtsova GF; Olopade OI; Mazo A; Bargonetti J
Cancer Res; 2020 Feb; 80(3):394-405. PubMed ID: 31776133
[TBL] [Abstract][Full Text] [Related]
59. METTL3 inhibits hepatic insulin sensitivity via N6-methyladenosine modification of Fasn mRNA and promoting fatty acid metabolism.
Xie W; Ma LL; Xu YQ; Wang BH; Li SM
Biochem Biophys Res Commun; 2019 Oct; 518(1):120-126. PubMed ID: 31405565
[TBL] [Abstract][Full Text] [Related]
60. The m6A methyltransferase METTL3 promotes osteosarcoma progression by regulating the m6A level of LEF1.
Miao W; Chen J; Jia L; Ma J; Song D
Biochem Biophys Res Commun; 2019 Aug; 516(3):719-725. PubMed ID: 31253399
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]